General information about company						
Name of The Company	MARKSANS PHARMA LIMITED					
BSE Scrip Code	524404					
NSE Symbol	MARKSANS					
MSE Symbol	NA					
Date of Start of Financial Year	01-04-2023					
Date of End of Financial Year	31-03-2024					
Reporting Period	First half yearly					
Date of Start of Reporting Period	01-04-2023					
Date of End of Reporting Period	30-09-2023					
Level of rounding to be used in disclosing related party transactions	Millions					
Whether the company has any related party?	Yes					
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes					

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

								Re	elated par	ty transa	ctions						_
													relat	al disclosure of es to loans, int bsidiary. Thes	ter-cor	porate o	dep
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty					Value of the related			In case monies are due to either party as a result of the transaction		corporate deposits, advances or				
Sr No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	N ac e in do in
1	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Sale of goods or services		1852.139	Nil	259.93	0	0					T
2	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	292.22	0	0					Ī
3	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	658.79	0	0					Ī
4	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	1899.94	0	0					
5	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	435.12	350.18					
6	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	-98.83	-62					Ī
7	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	-697.39	-822.22					Ī
8	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	2151.1	2255.98					I
9	Marksans Pharma Limited	AAACT3153G	Marksans Pharma UK Limited	ZZZZZ9999Z	Wholly owned subsidiary	Dividend received			Nil	257.67	0	0					I
10	Marksans Pharma	AAACT3153G	Bell, Sons and Co. (Druggists)	ZZZZZ9999Z	Step down Subsidiary	Purchase of goods			Nil	0.93	0	0					

1	Limited		Limited		ĺ	or services				_			
11	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Purchase of goods or services		Nil	0.86	0	0		
12	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Purchase of goods or services		Nil	7.96	0	0		
13	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable	Nil	0	0.05	0.89		
14	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable	Nil	0	0.06	0.86		
15	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable	Nil	0	0.05	1.23		
16	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Any other transaction	Remuneration	Nil	40.184	0	0		
17	Marksans Pharma Limited	AAACT3153G	Sandra Saldanha	ALRPS8186P	Promoter & Key Managerial Personnel	Any other transaction	Remuneration	Nil	3.528	0	0		
18	Marksans Pharma Limited	AAACT3153G	Jitendra Sharma	AJCPS5121K	Key Managerial Personnel	Any other transaction	Remuneration	Nil	6.534	0	0		
19	Marksans Pharma Limited	AAACT3153G	Harshavardhan Panigrahi	AKTPP1644A	Key Managerial Personnel	Any other transaction	Remuneration	Nil	1.34	0	0		
20	Marksans Pharma Limited	AAACT3153G	Varddhman Jain	ACWPJ0702A	Key Managerial Personnel	Any other transaction	Remuneration	Nil	11.87	0	0		
21	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Key Managerial Personnel	Any other transaction	Rent Paid	Nil	5.326	0	0		

Total value of transaction during the reporting period

3447.082

	Text Block
Textual Information(1)	
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	
Textual Information(5)	
Textual Information(6)	
Textual Information(7)	
Textual Information(8)	
Textual Information(9)	
Textual Information(10)	
Textual Information(11)	
Textual Information(12)	
Textual Information(13)	
Textual Information(14)	
Textual Information(15)	
Textual Information(16)	Remuneration of Rs. 34.40 million is drawn from the Company and the remaining amount (Rs. 5.79 million) is the remunratiuon drawn from subsidiary Company.
Textual Information(17)	
Textual Information(18)	
Textual Information(19)	
Textual Information(20)	
Textual Information(21)	